> Finland's Orion Corp. says that Phase II data for its oral heart drug levosimendan weren't good enough to warrant a late-stage trial. Report

> The FDA has granted Xechem orphan drug status for a sickle cell therapy. Report

> Amgen has agreed to pay Massachusetts General $186 million to settle all royalty claims over the rheumatoid arthritis drug Enbrel. Report

> The U.S. subsidiary of India's Glenmark Pharmaceuticals has signed a deal in which Paul Capital Partners Royalty Fund will invest $27 million to finance the development of 16 dermatological products. Report

> Chutes & Ladders: Isolagen has named Nicholas L. Teti Jr. as its new chairman and CEO. Report

> P&G and Hoffman-LaRoche are fighting a court battle over the ad claims made for the osteoporosis drug Boniva. Report

> Charles River Laboratories has plans to issue $300 million in notes to investors. Report

> Wyeth and Progenics have outlined plans for their joint development of methylnaltrexone. Report

> Acusphere says that an experimental new system for testing coronary heart disease met two of three goals in a late-stage trial. Report

And Finally…The use of antipsychotics among children and adolescents increased fivefold between 1993 and 2002. Article